Showing results (91-100 of 103) with videos related to
Sort By:
Pageof 11
Oral Diseases|November 19, 2025
The Role of the Mylohyoid Line in the Spread of Mandibular Odontogenic Deep Neck InfectionEiji Iwata, Kyoichi Obata, Shogo Kikuta, et al.Odontology|July 4, 2025
Admission prognostic nutritional index predicts prolonged hospitalization in severe odontogenic deep neck infectionsEiji Iwata, Kyoichi Obata, Shogo Kikuta, et al.The Prostate|July 16, 2026
Evaluating Risk Factors Associating With Late Recurrence After Low-Dose-Rate Brachytherapy for Prostate Cancer Using Machine LearningKenta Onishi, Tomonori Nakahama, Yasushi Nakai, et al.Journal of Radiation Research|February 4, 2012
Mitochondria-targeted superoxide dismutase (SOD2) regulates radiation resistance and radiation stress response in HeLa cellsAyaka Hosoki, Shin-Ichiro Yonekura, Qing-Li Zhao, et al.Cancers|February 24, 2024
Impact of Complete Surgical Resection of Metastatic Lesions in Patients with Advanced Renal Cell Carcinoma in the Era of Tyrosine Kinase Inhibitors and Immune Checkpoint InhibitorsTakuto Shimizu, Makito Miyake, Nobutaka Nishimura, et al.Journal of Orthopaedic Science : Official Journal of the Japanese Orthopaedic Association|March 1, 2020
Treatment outcomes of adjunctive teriparatide therapy for medication-related osteonecrosis of the jaw (MRONJ): A multicenter retrospective analysis in JapanKota Morishita, Shin-Ichi Yamada, Akiko Kawakita, et al.Bladder Cancer (Amsterdam, Netherlands)|March 24, 2025
Platinum-based chemotherapy rechallenge or enfortumab vedotin after maintenance avelumab or pembrolizumab for locally advanced or metastatic urothelial carcinomaNobutaka Nishimura, Makito Miyake, Norimi Takamatsu, et al.Japanese Journal of Clinical Oncology|December 9, 2022
Switch-maintenance avelumab immunotherapy following first-line chemotherapy for patients with advanced, unresectable or metastatic urothelial carcinoma: the first Japanese real-world evidence from a multicenter studyMakito Miyake, Takuto Shimizu, Yuki Oda, et al.Clinical Genitourinary Cancer|December 17, 2021
Response to Pembrolizumab After Dose-Reduced Cisplatin Plus Gemcitabine Chemotherapy Is Inferior to That After Carboplatin Plus Gemcitabine Chemotherapy in Cisplatin-Unfit Patients With Advanced Urothelial CarcinomaMakito Miyake, Takuto Shimizu, Nobutaka Nishimura, et al.Journal of Dental Sciences|July 5, 2023
Incidence of antiresorptive agent-related osteonecrosis of the jaw: A multicenter retrospective epidemiological study in Hyogo Prefecture, JapanMasanori Nashi, Hiromitsu Kishimoto, Masaki Kobayashi, et al.Pageof 11